公司資料
Alvotech 股價、新聞與催化劑
- 股票代碼:
- ALVO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Iceland
股票表現
5.62 USD (-3.10%)
收盤價
最後更新: 2026年10月1日
936M USD
市值
股價為何變動
最新監測到的公司動態為「Matvæla- og lyfjastofnun Bandaríkjanna (FDA) veitir viðbótarleyfi fyrir framleiðslu á hliðstæðunni við Humira í báðum framleiðslueiningum lyfjaverksmiðju Alvotech í Reykjavík」。相應的收盤價反應尚未產生。
公司概覽
Global Biosimilar Developer and Manufacturer
Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional marketing partners.
Commercial Biosimilar Portfolio
The marketed portfolio includes biosimilars referencing Humira and Stelara, providing exposure to large immunology markets. Additional products referencing Prolia/Xgeva, Simponi/Simponi Aria, and Eylea broaden the portfolio into bone disease and ophthalmology.
Global Partnership Model
Alvotech generally partners with regional pharmaceutical companies for commercialization while retaining responsibility for development and manufacturing. This structure gives the company access to many markets without building a fully owned sales organization in every country.
Manufacturing-Centered Strategy
Complex biologic manufacturing is a core competitive capability. Alvotech's facilities support development through commercial supply, and regulatory inspections, manufacturing readiness, and reliable scale-up are critical to both product approvals and partner launches.
Expanding Late-Stage Pipeline
The pipeline includes AVT03, AVT05, AVT06, AVT16, AVT80, and additional biosimilars targeting high-value biologics across immunology, ophthalmology, oncology, and other specialty markets. Multiple candidates are being reviewed across the United States, Europe, and additional international jurisdictions.
未來催化劑
- FDA regulatory decisions in the fourth quarter of 2026 for resubmitted applications covering AVT03, AVT05, and AVT06.
- Regulatory decisions for additional late-stage biosimilars AVT16 and AVT80 following ongoing U.S. and European reviews.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。